You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Anti-TIGIT

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Solid Tumor Trial in Bengbu (HB0030 injection)

Recruiting
  • Advanced Solid Tumor
  • HB0030 injection
  • Bengbu, Anhui, China
    the First Affiliated Hospital of Bengbu Medical College
Jan 20, 2023

Advanced Tumor Trial (PM1009 injection)

Not yet recruiting
  • Advanced Tumor
  • PM1009 injection
  • (no location specified)
Nov 7, 2022

Advanced Solid Tumours Trial (PM1021, PM8001)

Not yet recruiting
  • Advanced Solid Tumours
  • PM1021, PM8001
  • (no location specified)
Sep 12, 2022

Advanced Tumors, Lymphoma, Metastatic Tumors Trial in Changchun, Jinan (HLX301)

Recruiting
  • Advanced Tumors
  • +2 more
  • Changchun, Jilin, China
  • +1 more
Jul 12, 2022

Solid Tumor, Adult Trial in Albury (Tiragolumab, Atezolizumab)

Not yet recruiting
  • Solid Tumor, Adult
  • Tiragolumab
  • Atezolizumab
  • Albury, New South Wales, Australia
  • +1 more
Aug 22, 2023

Locally Advanced or Metastatic Solid Tumors, NSCLC Trial in Australia (HLX301)

Recruiting
  • Locally Advanced or Metastatic Solid Tumors
  • Non-small Cell Lung Cancer
  • Blacktown, New South Wales, Australia
  • +4 more
May 25, 2022

Advanced Solid Tumor, NSCLC Trial (HB0036)

Recruiting
  • Advanced Solid Tumor
  • NSCLC
  • San Antonio, Texas
    Next Oncology
Sep 14, 2022

Biliary Tract Carcinoma Trial in Shanghai (GP+PD-1+Tight)

Recruiting
  • Biliary Tract Carcinoma
  • Shanghai, China
    Zhongshan hospital
Mar 22, 2022

Glioblastoma Trial in New Haven (AB122, AB154, Placebo)

Recruiting
  • Glioblastoma
  • New Haven, Connecticut
    Yale University
Jul 5, 2022

Advanced Solid Tumor, NSCLC, Hepatocellular Carcinoma Trial in Canton (CHS-006 (anti-TIGIT), toripalimab (anti-PD-1))

Not yet recruiting
  • Advanced Solid Tumor
  • +2 more
  • CHS-006 (anti-TIGIT)
  • toripalimab (anti-PD-1)
  • Canton, Ohio
    Gabrail Cancer and Research Center
Feb 23, 2023

Advanced Tumors Trial in Guangzhou (JS006 as Monotherapy, JS006 in combination with Toripalimab)

Recruiting
  • Advanced Tumors
  • JS006 as Monotherapy
  • JS006 in combination with Toripalimab
  • Guangzhou, Guangdong, China
    Sun Yat-Sen University Cancer Center
Sep 21, 2021

Intrahepatic Cholangiocarcinoma Trial in Shanghai (GP+PD-1+Tight)

Withdrawn
  • Intrahepatic Cholangiocarcinoma
  • Shanghai, Shanghai, China
    Zhongshan hospital, Fudan University
Mar 22, 2022

Advanced Malignant Tumors Trial (AK130)

Not yet recruiting
  • Advanced Malignant Tumors
  • (no location specified)
Dec 7, 2022

Advanced Malignancies Trial in Beijing (IBI939, IBI939+ Sintilimab)

Active, not recruiting
  • Advanced Malignancies
  • Beijing, China
    Peking University Cancer Hospital & Institute
Oct 4, 2022

Cancer, Carcinoma, Squamous Cell Carcinoma Trial in San Francisco (Atezolizumab, Tocilizumab, Tiragolumab)

Recruiting
  • Cancer
  • +3 more
  • Atezolizumab
  • +2 more
  • San Francisco, California
    University of San Francisco, California
Feb 1, 2022

Advanced Solid Tumor Trial in Liverpool (BAT6021, BAT1308)

Recruiting
  • Advanced Solid Tumor
  • Liverpool, New South Wales, Australia
    Medical Oncologist at cancer Therapy, Liverpool Hospital
Nov 14, 2021

Non-Small-Cell Lung Carcinoma Trial in Worldwide (AZD2936)

Recruiting
  • Non-Small-Cell Lung Carcinoma
  • Orange, California
  • +29 more
Aug 18, 2022

Endometrial Tumors, Ovarian Cancer, Solid Tumor Trial in United States (COM701 in combination with BMS-986207 and nivolumab.)

Recruiting
  • Endometrial Neoplasms
  • +3 more
  • COM701 in combination with BMS-986207 and nivolumab.
  • Chicago, Illinois
  • +8 more
Aug 8, 2022

Recurrent Fallopian Tube Clear Cell Adenocarcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Platinum-Resistant

Recruiting
  • Recurrent Fallopian Tube Clear Cell Adenocarcinoma
  • +5 more
  • Etigilimab
  • Nivolumab
  • Houston, Texas
    M D Anderson Cancer Center
Nov 22, 2021

Esophageal Squamous Cell Carcinoma Trial in Worldwide (Tislelizumab, Ociperlimab, Placebo)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Hefei, Anhui, China
  • +85 more
Aug 19, 2022

Locally Advanced Cancer, Metastatic Cancer Trial in United States (OMP-313M32, Nivolumab)

Terminated
  • Locally Advanced Cancer
  • Metastatic Cancer
  • Scottsdale, Arizona
  • +4 more
Aug 10, 2020

Metastatic Solid Tumors Trial in Canada, United States (M6223, Bintrafusp alfa)

Recruiting
  • Metastatic Solid Tumors
  • Nashville, Tennessee
  • +3 more
Oct 14, 2021

Head and Neck Tumors, MSI-H Cancer, Melanoma Trial (Tiragolumab and atezolizumab)

Not yet recruiting
  • Head and Neck Neoplasms
  • +2 more
  • Tiragolumab and atezolizumab
  • (no location specified)
Aug 1, 2022

Locally Advanced Esophageal Squamous Cell Carcinoma Trial (Tiragolumab)

Not yet recruiting
  • Locally Advanced Esophageal Squamous Cell Carcinoma
  • (no location specified)
Feb 23, 2023

NSCLC Trial in Worldwide (Atezolizumab, Tiragolumab, Placebo)

Active, not recruiting
Has Results
  • Non-small Cell Lung Cancer
  • Tempe, Arizona
  • +40 more
Nov 11, 2022